Overview

Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to explore the efficacy, safety and cognitive properties of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lundbeck A/S
Treatments:
Risperidone